Chief Business Officer
Ellen is responsible for Business and Corporate Development activities and strategy, including aspects of Investor Relations. She brings to Impel nearly 20 years of biopharmaceutical industry experience, including global partnering, asset sourcing and acquisition, financial structuring and leading early-stage company operations, fundraising and board governance. Prior to joining Impel, she served as the Vice President of External Science & Innovation at Allergan, where she was responsible for strategic expansion of the company’s pipeline in a variety of disease areas, including Alzheimer’s disease, Parkinson’s disease and autism. Prior to joining Allergan, Ellen served in financial, strategic, commercial and corporate development executive positions at Kadmon Pharmaceuticals, Bristol-Myers Squibb, Celtic Pharma Management, L.P., Robertson Stephens Investment Bank and Abbott Labs. She has her MBA from Stanford Graduate School of Business with a focus on Global Management and her B.A. in Biology from Rutgers College. Ellen also serves on the Board of Directors of GeneCentric Therapeutics and is on the Scientific Advisory Board of the Daedalus Innovation Fund of Weill-Cornell.